Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Former Federal Reserve Chairman Alan Greenspan passes away at the age of 100

Former Federal Reserve Chairman Alan Greenspan passes away at the age of 100

老虎证券老虎证券2026/06/22 11:24
Show original
He served as the Chairman of the Federal Reserve five times, overseeing U.S. monetary policy during the terms of four American presidents. From the end of the Cold War to the dawn of the digital age, Greenspan profoundly shaped the trajectory of modern American capitalism. While leading the Federal Reserve, he witnessed the longest economic expansion cycle in U.S. history, with the boom lasting from 1991 to 2001. However, many critics have pointed out that several policies he implemented laid the groundwork for the 2007–2008 global financial crisis.Mitchell stated, “Alan passed away at home this morning at the age of 100, due to complications from Parkinson’s disease.” “He was a giant of his era, deeply influencing the direction of the American economy over decades and under multiple presidents from both parties. At the same time, he always candidly faced his own decision-making mistakes,” she said.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

BUZZ-Genmab shares hit a three-year high as blood cancer drug combination study results are released

October 6 - Genmab (GMAB.CO) shares rose about 8%, reaching a three-year high and leading the STOXX 600 index (.STOXX). Genmab and AbbVie ABBV.N announced on Monday (link) that their combination therapy for blood cancer reduced the risk of disease progression and death in a late-stage clinical trial. The two companies stated that, compared to R-CHOP regimen alone, the combination therapy reduced the risk of disease progression or death in newly diagnosed patients by 51%. Analysts at Jefferies described this result as "impressive". The brokerage added that the data "easily met the bar for success" and exceeded investor expectations of approximately 40%. TD Cowen stated that the data establishes the combination therapy as a potential new standard of care, with peak market potential expected to exceed $3 billion. (For convenience of non-English speakers, Reuters has automated this report into several other languages. Automated translations may contain errors or lack necessary context, and Reuters makes no guarantees as to their accuracy. The automated translation is provided for reader convenience, and Reuters bears no responsibility for any damages or losses resulting from use of the automated translation.)

路透社•2026/10/06 07:26